Difficulty: Medium
Average Score: 86%
Practice
Ticlopidine is an inhibitor of ADP-induced platelet aggregation. ItÔÇÖs:
Correct answer
A
Rationale
Step-by-step rationale:
1. Ticlopidine is a thienopyridine derivative that inhibits ADP-induced platelet aggregation.
2. By inhibiting the binding of ADP to its platelet receptor, it prevents platelet activation and aggregation.
3. This mechanism of action makes ticlopidine an effective antiplatelet medication for preventing clot formation.
4. Therefore, the statement that ticlopidine is an inhibitor of ADP-induced platelet aggregation is TRUE.
Summary of other choices:
- Choice B (FALSE): This is incorrect as ticlopidine is indeed an inhibitor of ADP-induced platelet aggregation.
- Choice C (All): This is incorrect as ticlopidine is not classified as affecting all types of platelet aggregation.
- Choice D (None of the above): This is incorrect as the correct answer is A, making this choice invalid.
1. Ticlopidine is a thienopyridine derivative that inhibits ADP-induced platelet aggregation.
2. By inhibiting the binding of ADP to its platelet receptor, it prevents platelet activation and aggregation.
3. This mechanism of action makes ticlopidine an effective antiplatelet medication for preventing clot formation.
4. Therefore, the statement that ticlopidine is an inhibitor of ADP-induced platelet aggregation is TRUE.
Summary of other choices:
- Choice B (FALSE): This is incorrect as ticlopidine is indeed an inhibitor of ADP-induced platelet aggregation.
- Choice C (All): This is incorrect as ticlopidine is not classified as affecting all types of platelet aggregation.
- Choice D (None of the above): This is incorrect as the correct answer is A, making this choice invalid.